

Hong Gao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3587322/publications.pdf>

Version: 2024-02-01

19
papers

41,994
citations

777949

13
h-index

799663

21
g-index

21
all docs

21
docs citations

21
times ranked

79348
citing authors

#	ARTICLE	IF	CITATIONS
1	The Effects of ATIR Blocker on the Severity of COVID-19 in Hypertensive Inpatients and Virulence of SARS-CoV-2 in Hypertensive hACE2 Transgenic Mice. <i>Journal of Cardiovascular Translational Research</i> , 2022, 15, 38-48.	1.1	3
2	Integrated histopathological, lipidomic, and metabolomic profiles reveal mink is a useful animal model to mimic the pathogenicity of severe COVID-19 patients. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 29.	7.1	12
3	Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 124.	7.1	15
4	Safety and protective capability of an inactivated SARS-CoV-2 vaccine on pregnancy, lactation and the growth of offspring in hACE2 mice. <i>Vaccine</i> , 2022, 40, 4609-4616.	1.7	8
5	Susceptibility and Attenuated Transmissibility of SARS-CoV-2 in Domestic Cats. <i>Journal of Infectious Diseases</i> , 2021, 223, 1313-1321.	1.9	46
6	Hypofractionated versus conventionally fractionated image-guided volumetric-modulated arc radiotherapy for localized prostate cancer: a phase II randomized trial from China. <i>Aging</i> , 2021, 13, 6936-6944.	1.4	3
7	Sequential infection with H1N1 and SARS-CoV-2 aggravated COVID-19 pathogenesis in a mammalian model, and co-vaccination as an effective method of prevention of COVID-19 and influenza. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 200.	7.1	41
8	SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 337.	7.1	157
9	Laboratory biosafety emergency management for SARS-CoV-2. <i>Journal of Biosafety and Biosecurity</i> , 2020, 2, 99-101.	1.4	7
10	A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. <i>Nature</i> , 2020, 586, 572-577.	13.7	630
11	The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. <i>Nature</i> , 2020, 583, 830-833.	13.7	992
12	Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in rhesus macaques. <i>Nature Communications</i> , 2020, 11, 4400.	5.8	161
13	Development of an inactivated vaccine candidate for SARS-CoV-2. <i>Science</i> , 2020, 369, 77-81.	6.0	1,180
14	Development of an Inactivated Vaccine Candidate, BBIBP-CoV, with Potent Protection against SARS-CoV-2. <i>Cell</i> , 2020, 182, 713-721.e9.	13.5	639
15	Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. <i>Science</i> , 2020, 369, 818-823.	6.0	416
16	Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. <i>Lancet</i> , The, 2020, 395, 497-506.	6.3	36,800
17	Age-related rhesus macaque models of COVID-19. <i>Animal Models and Experimental Medicine</i> , 2020, 3, 93-97.	1.3	238
18	Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 via Close Contact and Respiratory Droplets Among Human Angiotensin-Converting Enzyme 2 Mice. <i>Journal of Infectious Diseases</i> , 2020, 222, 551-555.	1.9	61

#	ARTICLE	IF	CITATIONS
19	Treatment With Lopinavir/Ritonavir or Interferon- β Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. <i>Journal of Infectious Diseases</i> , 2015, 212, 1904-1913.	1.9	572